Health Care International - Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-free Survival For Patients With Relapsed/refractory Mantle Cell Lymphoma
Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients with relapsed and/or refractory (failed front line therapy and unresponsive to most recent treatment) mantle cell
Comments